Viusid in Adults With Acute Fever of Viral Etiology
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01008007 |
Recruitment Status
:
Completed
First Posted
: November 5, 2009
Last Update Posted
: May 18, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Fever of Viral Etiology | Dietary Supplement: Viusid Drug: Conventional treatment | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Effect of VIUSID Administration on Adults With Acute Fever of Viral Etiology |
Study Start Date : | September 2009 |
Actual Primary Completion Date : | May 2010 |
Actual Study Completion Date : | May 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: A
Viusid in combination with the conventional treatment for acute fever of viral etiology
|
Dietary Supplement: Viusid
One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
|
Active Comparator: B
Conventional treatment for acute fever of viral etiology
|
Drug: Conventional treatment
Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
|
- The platelet count improvement at 6 days (end of the treatment) [ Time Frame: 6 days ]
- The leukocyte count improvement at 6 days (end of the treatment) [ Time Frame: 6 days ]
- The granulocyte count improvement at 6 days (end of the treatment) [ Time Frame: 6 days ]
- Clinical symptoms disappear during the Viusid administration (6 days). [ Time Frame: 6 days ]
- Adverse effects during treatment [ Time Frame: 6 days ]
- Hemoglobin level improvement [ Time Frame: 6 days ]
- Hematocrit level improvement at 6 days (end of the treatment) [ Time Frame: 6 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Acute fever of viral etiology with less than 72 hours of progression
- Signed informed consent.
Exclusion Criteria:
- Patients under treatment with other antioxidants.
- Inability to swallow the content of Viusid bags

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01008007
Cuba | |
"Salvador Allende" Clinical-Surgical Hospital | |
Havana City, Havana, Cuba |
Principal Investigator: | Mayra R Carrasco García, MD | "Salvador Allende" Clinical-Surgical Hospital |
Responsible Party: | Mayra R. Carrasco García, "Salvador Allende" Clinical-Surgical Hospital |
ClinicalTrials.gov Identifier: | NCT01008007 History of Changes |
Other Study ID Numbers: |
CAT-0911-CU |
First Posted: | November 5, 2009 Key Record Dates |
Last Update Posted: | May 18, 2010 |
Last Verified: | May 2010 |
Keywords provided by Catalysis SL:
Viusid Dietary supplements Acute fever Viral etiology |
Additional relevant MeSH terms:
Fever Body Temperature Changes Signs and Symptoms |